Hypercholesterolemia is a medical condition often characterized by high levels of
low-density lipoprotein cholesterol (
LDL-C) in the blood. Despite the available
therapies, not all patients show sufficient responses, especially those with very high levels of
LDL-C or those with
familial hypercholesterolemia. Regulation of plasma
cholesterol levels is very complex and several
proteins are involved (both receptors and
enzymes). From these, the
proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising pharmacologic target. The objective of this work is to develop a new approach to inactivate PCSK9 by splice-switching
oligonucleotides (SSOs), converting the normal splice form to a natural, less abundant and inactive, splice variant. For this purpose, a new
RNA therapeutic approach for
hypercholesterolemia based on SSOs was developed for modulation of the splice pattern of human PCSK9
pre-mRNA. Our results show an increase of the selected splice form at both the
mRNA and
protein level when compared to non-treated Huh7 and HepG2 cell lines, with concomitant increase of the
protein level of the
low-density lipoprotein receptor (LDLR) demonstrating the specificity and efficiency of the system. In vivo, full conversion to the splice form was achieved in a reporter system when mice were treated with the specific
oligonucleotide, thus further indicating the therapeutic potential of the approach. In conclusion, PCSK9 activity can be modulated by splice-switching through an
RNA therapeutic approach. The tuning of the natural active to non-active
isoforms represents a physiological way of regulating the
cholesterol metabolism, by controlling the amount of
LDL receptor available and the rate of
LDL-cholesterol clearance.